Financial Data and Key Metrics - The company ended the quarter with $613 million in cash, cash equivalents, and short-term investments, maintaining a cash runway into the second half of 2026 [11][41] Business Line Data and Key Metrics - The THRIVE Phase 3 trial for VRDN-001 in active thyroid eye disease (TED) completed enrollment in March 2024 with 113 patients, exceeding the target of 90 due to strong patient demand [9][24] - The company anticipates filing a Biologics License Application (BLA) for VRDN-001 in the second half of 2025 [10] - The subcutaneous VRDN-003 program completed a positive Type C meeting with the FDA and is on track to initiate pivotal clinical trials mid-year 2024 [10][35] - The FcRn portfolio is progressing as planned, with an IND submission for VRDN-006 expected by the end of 2024 and non-human primate data for VRDN-008 expected in the second half of 2024 [11][39] Market Data and Key Metrics - The U.S. market for moderate to severe TED is estimated at 190,000 patients, with the current standard of care generating approximately $1.8 billion in U.S. sales in 2023 [13][14] - The TED market is considered a "new start market," meaning patients can choose from available treatments during each flare-up without displacing chronic therapies [15][16] Company Strategy and Industry Competition - The company aims to develop differentiated therapies for unmet medical needs, focusing on both IV and subcutaneous delivery options for TED and FcRn inhibitors for autoimmune diseases [7][36] - VRDN-001 is positioned as a potential best-in-class IV therapy with fewer doses and shorter infusion times compared to the current standard of care [27][28] - VRDN-003 is designed to offer a best-in-class subcutaneous dosing profile with the potential for at-home self-administration, which could significantly expand the market [29][31] Management Commentary on Operating Environment and Future Outlook - Management highlighted strong execution across the pipeline, with key catalysts including THRIVE top-line results in September 2024 and THRIVE-2 top-line results at the end of 2024 [40][41] - The company remains well-capitalized and is focused on delivering on upcoming milestones [41] Other Important Information - The company is conducting the STRIVE study to complete the safety database for the BLA submission of VRDN-001, with a data cut expected once the requisite number of patients is reached [26][72] - VRDN-003 demonstrated an extended half-life of 40-50 days in healthy volunteers, supporting its potential as a best-in-class subcutaneous therapy [32][34] Q&A Session Summary Question: What defines success for the THRIVE trial? - Success for THRIVE would be a safety and efficacy profile similar to TEPEZZA, with potential improvements in hearing impairment due to lower drug exposure [44][45] Question: How is the company addressing safety concerns in THRIVE? - The company is using standard methodologies for adverse event reporting and audiometry to monitor hearing, consistent with FDA guidance and current clinical practice [51][58] Question: What are the plans for VRDN-003 pivotal trials? - The company had a positive Type C meeting with the FDA and is on track to initiate pivotal trials mid-2024, with more details to be provided after receiving meeting minutes [56][62] Question: How does the company view the competitive landscape in TED? - The company sees strong patient demand for IGF-1R therapies, as evidenced by the over-enrollment in THRIVE, and believes its subcutaneous VRDN-003 could be a game-changer in the market [79][90] Question: What is the timeline for FcRn data? - Non-human primate data for VRDN-008 is expected in the second half of 2024, with healthy volunteer data for VRDN-006 anticipated in the second half of 2025 [91][92] Question: How does the company plan to expand internationally? - The company is considering ex-U.S. markets, particularly Europe, where the epidemiology of TED is similar to the U.S., but specific plans will be shared at a later time [66]

Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | - ...

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track for topline readout by year-end 2024 - Thyroid Eye Disease Portfolio VRDN-001, an intravenously delivered anti- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisdi ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone - Manager, IR Scott Myers - President and CEO Kristian Humer - Chief Financial and Business Officer Dr. Thomas Ciulla - Chief Development Officer Todd James - SVP, Corporate Affairs and IR Conference Call Participants Derek Archila - Wells Fargo Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities Ja ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 221 Crescent Street, Suite 401, Waltham, MA 02453 (Address of principal executive offices) Registrant's telephone number, inclu ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q4 2022 Earnings Conference Call March 8, 2023 8:00 AM ET Company Participants Louisa Stone - Manager, Investor Relations Scott Myers - President and Chief Executive Officer Kristian Humer - Chief Financial Officer Deepa Rajagopalan - Chief Product and Strategy Officer Todd James - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Gavin Clark-Gartner - Evercore ISI Laura Chico - Wedbush Securities Jason Butler - JMP Securit ...